Evidence map›Paper›PMID 31346130›Full record

Trial reportThe oncologist2019

Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.

Emil Lou, Rachel I Vogel, Spencer Hoostal, Phillip Wong, Aaron Grad, Minnu Monu, Tomasz Łukaszewski, Jaai Deshpande, Elizabeth L Dickson, Molly Klein and 4 more

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Emil LouUniversity of Minnesota, Minneapolis, Minnesota, USA emil-lou@umn.edu.
Rachel I VogelUniversity of Minnesota, Minneapolis, Minnesota, USA.
Spencer HoostalUniversity of Minnesota, Minneapolis, Minnesota, USA.
Phillip WongUniversity of Minnesota, Minneapolis, Minnesota, USA.
Aaron GradUniversity of Minnesota, Minneapolis, Minnesota, USA.
Minnu MonuUniversity of Minnesota, Minneapolis, Minnesota, USA.
Tomasz ŁukaszewskiUniversity of Minnesota, Minneapolis, Minnesota, USA.
Jaai DeshpandeUniversity of Minnesota, Minneapolis, Minnesota, USA.
Elizabeth L DicksonUniversity of Minnesota, Minneapolis, Minnesota, USA.
Molly KleinUniversity of Minnesota, Minneapolis, Minnesota, USA.
Michael A LindenUniversity of Minnesota, Minneapolis, Minnesota, USA.
Subbaya SubramanianUniversity of Minnesota, Minneapolis, Minnesota, USA.
Deanna TeohUniversity of Minnesota, Minneapolis, Minnesota, USA.
Melissa A GellerUniversity of Minnesota, Minneapolis, Minnesota, USA.
University of Minnesota · USAurora Health Care · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR000114NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

lesson learnedCirculating tumor cells, microRNA markers, or other biomarkers merit examination as part of correlative scientific analyses in prospective clinical trials.

backgroundPlatinum chemotherapy resistance occurs in approximately 25% of patients with ovarian carcinoma; however, no biomarkers of ovarian carcinoma chemoresistance have been validated. We performed a prospective trial designed to identify tumor-based predictive biomarkers of platinum resistance.

methodsTumor specimens were collected from 29 women with newly diagnosed histopathologically proven primary ovarian carcinoma. Of these, 23 women had specimens accessible for assessment and outcome data available regarding chemosensitive versus chemoresistance status via review of the medical record. Tumor slices were stained with antibodies against two microRNAs (miRNAs 29b and 199a) differentially expressed in chemoresistant ovarian cancer cell lines. Additionally, blood samples obtained at the time of diagnosis were analyzed for the presence of circulating tumor cells (CTCs).

resultsThe average age of the patients was 64 years, and 82.6% had high-grade epithelial carcinomas. The baseline median CA-125 was 464 (range 32-2,782). No statistically significant differences were observed in miR29b or 199a expression in platinum-resistant/refractory versus platinum-sensitive tumors. Furthermore, the presence of CTCs was not found to be statistically significantly predictive of eventual platinum resistance.

conclusionOur analysis showed no differences in miR29b and 199a expression, and differences in baseline CTCs in women with newly diagnosed ovarian tumors were not statistically significant.

Indexed as

Drug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansMicroRNAsMiddle AgedNeoplasm Recurrence, LocalNeoplastic Cells, CirculatingOvarian NeoplasmsPlatinumPrognosisProspective StudiesSurvival RateBiomarkers, TumorMicroRNAsmirn199 microRNA, humanMIRN29a microRNA, humanPlatinum

Identifiers

PMID31346130
PMCPMC6853113
OpenAlexW2963873518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.